IHC PD-L1 Lung (Pembrolizumab)
IHC PD-L1 Lung (Pembrolizumab) assesses the expression of PD-L1 (Programmed Death-Ligand 1) in lung tissue, guiding the use of immunotherapy with pembrolizumab for lung cancer.
IHC PD-L1 Lung (Pembrolizumab)
IHC PD-L1 Lung (Pembrolizumab)
